what are Analysts report about: Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN)


Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) will report its next earnings on Nov 1 – Nov 7 (Est.). The company reported the earnings of $-0.01/Share in the last quarter where the estimated EPS by analysts was $-0.02/share. The difference between the expected and actual EPS was $0.01/share, which represents an Earnings surprise of 50%.

Many analysts are providing their Estimated Earnings analysis for Rexahn Pharmaceuticals, Inc. and for the current quarter 2 analysts have projected that the stock could give an Average Earnings estimate of $-0.02/share. These analysts have also projected a Low Estimate of $-0.02/share and a High Estimate of $-0.02/share.

Some buy side analysts are also providing their Analysis on Rexahn Pharmaceuticals, Inc., where 1 analysts have rated the stock as Strong buy, 1 analysts have given a Buy signal, 0 said it’s a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. 2 Analysts reported that the Price Target for Rexahn Pharmaceuticals, Inc. might touch $3 high while the Average Price Target and Low price Target is $2.5 and $2 respectively.

To analyze a stock, one should look for Upgrades and Downgrades of a stock. Rexahn Pharmaceuticals, Inc. got Initiated on 20-Mar-15 where investment firm MLV & Co Initiated the stock to Buy.

Rexahn Pharmaceuticals, Inc. closed its last trading session at $0.18 with the loss of -5.23%. The Market Capitalization of the company stands at 40.82 Million. The Company has 52-week high of $0.52 and 52-week low of $0.16. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -18.41% where SMA50 and SMA200 are -27.64% and -41.38% respectively. The Company Touched its 52-Week High on Nov 5, 2015 and 52-Week Low on Oct 17, 2016.

The Relative Volume of the company is 1.43 and Average Volume (3 months) is 875.86 million. Rexahn Pharmaceuticals, Inc. P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of -54.5%. The Return on Equity (ROE) value stands at -73.6%. While it’s Return on Investment (ROI) value is 0%.

While looking at the Stock’s Performance, Rexahn Pharmaceuticals, Inc. currently shows a Weekly Performance of -16.87%, where Monthly Performance is -20.62%, Quarterly performance is -33.89%, 6 Months performance is -45.19% and yearly performance percentage is -63.37%. Year to Date performance value (YTD perf) value is -53.03%. The Stock currently has a Weekly Volatility of 11.03% and Monthly Volatility of 6.51%.